MGMT and neoplasm: Although we are not aware of data on the amount of O6MeG in the tumor tissue after TMZ treatment, it is reasonable to assume that O6MeG also accumulates in the MGMT-lacking tumor, leading to additive effects even when a low-dose (metronomic) schedule is used.